| β-内酰胺类联合大环内酯类药物治疗儿童社区获得性肺炎的有效性与安全性的Meta分析 |
| 投稿时间：2020-07-20 修订日期：2021-03-15 点此下载全文 |
| 引用本文：葛佳佳,张莹莹.β-内酰胺类联合大环内酯类药物治疗儿童社区获得性肺炎的有效性与安全性的Meta分析[J].药学实践杂志,2021,39(3):274~279 |
| 摘要点击次数: 809 |
| 全文下载次数: 638 |
|
|
| 中文摘要:目的 比较β-内酰胺类联合大环内酯类与单用β-内酰胺类药物治疗儿童社区获得性肺炎（CAP）的有效性与安全性。方法 检索PubMed、CNKI和VIP数据库，搜集使用β-内酰胺类联合大环内酯类治疗儿童CAP患儿的相关随机对照试验（RCT），检索时限为自建库至2020年7月。按照纳入与排除标准筛选文献、提取所需数据，采用RevMan 5.3软件进行Meta分析。结果 有13篇文献纳入研究，共1 788例儿童患者。结果显示，试验组联合用药的临床有效率优于对照组[RR=1.11, CI=1.07～1.15, P<0.000 01]，发热消退至正常的时间短于对照组[MD=-1.31, CI=-1.58～-1.05, P<0.000 01]，肺部啰音消失时间短于对照组[RR=-1.75, CI= -2.13～-1.37, P<0.000 01]，不良反应发生率两组无统计学意义（P> 0.05）。结论 当前证据表明，对于儿童CAP感染患者，β-内酰胺类联合大环内酯类的有效性优于单用β-内酰胺类药物，其不良反应两者无明显差异。因受纳入研究数量和质量所限，本研究结论尚需进一步开展大样本、高质量RCT进行验证。 |
| 中文关键词:β-内酰胺类 大环内酯类 儿童社区获得性肺炎 荟萃分析 |
| |
| Meta-analysis on the efficacy and safety of β- lactams combined with macrolides in the treatment of community-acquired pneumonia in children |
|
|
| Abstract:Objective To compare the efficacy and safety of β - lactams alone and the combination of β - lactams with macrolides in the treatment of community-acquired pneumonia(CAP) in children.Methods PubMed, CNKI and VIP databases were searched by computer. RCT on children with CAP treated by β-lactams and macrolides were collected. The retrieval time was from the establishment of the database to July 2020. Literatures were selected and data was extracted according to inclusion and exclusion criteria. The risk of bias was evaluated, RevMan 5.3 software was used for Meta-analysis.Results Thirteen articles with 1788 patients were included in the study. The results showed that the clinical efficacy of the combination therapy in the experimental group was better than that in the control group [RR = 1.11, CI = 1.07–1.15, P < 0.000 01]. The time for fever returning to normal was shorter in the experimental group than that in the control group [MD = -1.31, CI =-1.58– -1.05, P < 0.000 01]. The disappearance time of pulmonary rales was shorter in the experimental group than that in the control group [MD = -1.75, CI = -2.13– -1.37, P < 0.000 01], There was no statistically significant difference in adverse reactions between the two groups (P > 0.05).Conclusion The combination therapy of β - lactams and macrolides is better than β-lactams alone in children with CAP with no significant difference in adverse reactions. Limited by the quantity and quality of the included studies, the conclusions from this study need to be further verified by large samples of high-quality RCT. |
| keywords:β-lactams macrolides community acquired pneumonia in children Meta-analysis |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
| 关闭 |
|
|
|
